menu
    • menu
    [{"orgOrder":0,"company":"MapLight Therapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"U.S.A","productType":"Miscellaneous","year":"2024","type":"Inapplicable","leadProduct":"ML-007","moa":"M1\/M4 receptor","graph1":"Psychiatry\/Psychology","graph2":"Phase I","graph3":"MapLight Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Tablet","sponsorNew":"MapLight Therapeutics \/ Undisclosed","highestDevelopmentStatusID":"6","companyTruncated":"MapLight Therapeutics \/ Undisclosed"},{"orgOrder":0,"company":"MapLight Therapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"U.S.A","productType":"Miscellaneous","year":"2023","type":"Inapplicable","leadProduct":"ML-007","moa":"M1\/M4 receptor","graph1":"Psychiatry\/Psychology","graph2":"Phase I","graph3":"MapLight Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Tablet","sponsorNew":"MapLight Therapeutics \/ Undisclosed","highestDevelopmentStatusID":"6","companyTruncated":"MapLight Therapeutics \/ Undisclosed"},{"orgOrder":0,"company":"MapLight Therapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"U.S.A","productType":"Miscellaneous","year":"2024","type":"Inapplicable","leadProduct":"ML-007","moa":"||M1\/M4 receptor","graph1":"Psychiatry\/Psychology","graph2":"Phase I","graph3":"MapLight Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Tablet","sponsorNew":"MapLight Therapeutics \/ Undisclosed","highestDevelopmentStatusID":"6","companyTruncated":"MapLight Therapeutics \/ Undisclosed"},{"orgOrder":0,"company":"MapLight Therapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Miscellaneous","year":"2025","type":"Inapplicable","leadProduct":"ML-007C-MA","moa":"M1\/M4 receptor","graph1":"Neurology","graph2":"Phase II","graph3":"MapLight Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Tablet","sponsorNew":"MapLight Therapeutics \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"MapLight Therapeutics \/ Undisclosed"},{"orgOrder":0,"company":"MapLight Therapeutics","sponsor":"Organovo Holdings","pharmaFlowCategory":"D","therapeuticArea":"Psychiatry\/Psychology","country":"U.S.A","productType":"Miscellaneous","year":"2023","type":"Series C Financing","leadProduct":"ML-007C-MA","moa":"M1\/M4 receptor","graph1":"Psychiatry\/Psychology","graph2":"Phase II","graph3":"MapLight Therapeutics","amount2":0.23000000000000001,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Psychiatry","amount2New":0.23000000000000001,"dosageForm":"Undisclosed","sponsorNew":"MapLight Therapeutics \/ Organovo Holdings","highestDevelopmentStatusID":"8","companyTruncated":"MapLight Therapeutics \/ Organovo Holdings"},{"orgOrder":0,"company":"MapLight Therapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"U.S.A","productType":"Miscellaneous","year":"2025","type":"Inapplicable","leadProduct":"ML-007C-MA","moa":"M1\/M4 receptor","graph1":"Psychiatry\/Psychology","graph2":"Phase II","graph3":"MapLight Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"MapLight Therapeutics \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"MapLight Therapeutics \/ Undisclosed"},{"orgOrder":0,"company":"MapLight Therapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Undisclosed","year":"2021","type":"Inapplicable","leadProduct":"ML-004","moa":"Undisclosed","graph1":"Neurology","graph2":"Phase II","graph3":"MapLight Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Tablet","sponsorNew":"MapLight Therapeutics \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"MapLight Therapeutics \/ Undisclosed"},{"orgOrder":0,"company":"MapLight Therapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Undisclosed","year":"2023","type":"Inapplicable","leadProduct":"ML-004","moa":"Undisclosed","graph1":"Neurology","graph2":"Phase II","graph3":"MapLight Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Tablet","sponsorNew":"MapLight Therapeutics \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"MapLight Therapeutics \/ Undisclosed"},{"orgOrder":0,"company":"MapLight Therapeutics","sponsor":"Morgan Stanley","pharmaFlowCategory":"D","therapeuticArea":"Psychiatry\/Psychology","country":"U.S.A","productType":"Miscellaneous","year":"2025","type":"Public Offering","leadProduct":"ML-007C-MA","moa":"M1\/M4 receptor","graph1":"Psychiatry\/Psychology","graph2":"Phase II","graph3":"MapLight Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Psychiatry","amount2New":0.25,"dosageForm":"Tablet","sponsorNew":"MapLight Therapeutics \/ Morgan Stanley","highestDevelopmentStatusID":"8","companyTruncated":"MapLight Therapeutics \/ Morgan Stanley"},{"orgOrder":0,"company":"MapLight Therapeutics","sponsor":"Jefferies","pharmaFlowCategory":"D","therapeuticArea":"Psychiatry\/Psychology","country":"U.S.A","productType":"Miscellaneous","year":"2025","type":"Public Offering","leadProduct":"ML-007C-MA","moa":"M1\/M4 receptor","graph1":"Psychiatry\/Psychology","graph2":"Phase II","graph3":"MapLight Therapeutics","amount2":0.26000000000000001,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Psychiatry","amount2New":0.26000000000000001,"dosageForm":"Tablet","sponsorNew":"MapLight Therapeutics \/ Jefferies","highestDevelopmentStatusID":"8","companyTruncated":"MapLight Therapeutics \/ Jefferies"},{"orgOrder":0,"company":"MapLight Therapeutics","sponsor":"Morgan Stanley","pharmaFlowCategory":"D","therapeuticArea":"Psychiatry\/Psychology","country":"U.S.A","productType":"Miscellaneous","year":"2025","type":"Public Offering","leadProduct":"ML-007C-MA","moa":"M1\/M4 receptor","graph1":"Psychiatry\/Psychology","graph2":"Phase II","graph3":"MapLight Therapeutics","amount2":0.25,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Psychiatry","amount2New":0.25,"dosageForm":"Tablet, Extended Release","sponsorNew":"MapLight Therapeutics \/ Morgan Stanley","highestDevelopmentStatusID":"8","companyTruncated":"MapLight Therapeutics \/ Morgan Stanley"},{"orgOrder":0,"company":"MapLight Therapeutics","sponsor":"Morgan Stanley | Jefferies | Leerink Partners | Stifel","pharmaFlowCategory":"D","therapeuticArea":"Psychiatry\/Psychology","country":"U.S.A","productType":"Miscellaneous","year":"2025","type":"Public Offering","leadProduct":"ML-007C-MA","moa":"M1\/M4 receptor","graph1":"Psychiatry\/Psychology","graph2":"Phase II","graph3":"MapLight Therapeutics","amount2":0.29999999999999999,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Psychiatry","amount2New":0.29999999999999999,"dosageForm":"Tablet, Extended Release","sponsorNew":"MapLight Therapeutics \/ Morgan Stanley | Jefferies | Leerink Partners | Stifel","highestDevelopmentStatusID":"8","companyTruncated":"MapLight Therapeutics \/ Morgan Stanley | Jefferies | Leerink Partners | Stifel"}]

    Find Clinical Drug Pipeline Developments & Deals by MapLight Therapeutics

    Menu

    MapLight Therapeutics

    EVENTS

    • Webinars & Exhibitions

    DIGITAL CONTENT

    DEVELOPMENTS

    PharmaCompass
    Xls
    Filters Filter
    ×
    FILTER:
    filter
    Company Name
      filter

      Year

        filter

        DEALS // DEV.

          filter

          Country

            filter
            Sponsor
              filter

              Therapeutic Area

                filter

                Study Phase

                  filter

                  Deal Type

                    filter

                    Product Type

                      filter

                      Dosage Form

                        filter

                        Lead Product

                          filter

                          Target

                            Loading...
                            refresh Filters
                            refresh Reset Filter
                            refresh Reset Filter
                            price-trend All Developments

                            Therapeutic Area by Lead Product

                            Study Phase by Lead Product

                            Company by Lead Product

                            Top Deals by Deal Size (USD bn)

                            01

                            MapLight Therapeutics

                            U.S.A arrow
                            AIChE Annual Meeting
                            Not Confirmed

                            MapLight Therapeutics

                            U.S.A arrow
                            AIChE Annual Meeting
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : ML-007C-MA

                            Therapeutic Area : Psychiatry/Psychology

                            Study Phase : Phase II

                            Sponsor : Morgan Stanley | Jefferies | Leerink Partners | Stifel

                            Deal Size : $296.3 million

                            Deal Type : Public Offering

                            DEALS_DEV arrow-down

                            MapLight Therapeutics Closes IPO with Full Underwriters' Share Purchase Option Exercise

                            Details : The proceeds from the offering will be used to fund the clinical development of ML-007C-MA, a small molecule product targeting the M1/M4 receptor for central nervous system disorders.

                            Product Name : Undisclosed

                            Product Type : Miscellaneous

                            Upfront Cash : Undisclosed

                            October 29, 2025

                            Lead Product(s) : ML-007C-MA

                            Therapeutic Area : Psychiatry/Psychology

                            Highest Development Status : Phase II

                            Sponsor : Morgan Stanley | Jefferies | Leerink Partners | Stifel

                            Deal Size : $296.3 million

                            Deal Type : Public Offering

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            02

                            MapLight Therapeutics

                            U.S.A arrow
                            AIChE Annual Meeting
                            Not Confirmed

                            MapLight Therapeutics

                            U.S.A arrow
                            AIChE Annual Meeting
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : ML-007C-MA

                            Therapeutic Area : Psychiatry/Psychology

                            Study Phase : Phase II

                            Sponsor : Morgan Stanley

                            Deal Size : $250.0 million

                            Deal Type : Public Offering

                            DEALS_DEV arrow-down

                            MapLight Goes Public with $250M IPO to Fund Cobenfy Competitor

                            Details : The proceeds from the offering will be used to fund the clinical development of ML-007C-MA, a small molecule product targeting the M1/M4 receptor for the treatment of schizophrenia.

                            Product Name : Undisclosed

                            Product Type : Miscellaneous

                            Upfront Cash : Undisclosed

                            October 26, 2025

                            Lead Product(s) : ML-007C-MA

                            Therapeutic Area : Psychiatry/Psychology

                            Highest Development Status : Phase II

                            Sponsor : Morgan Stanley

                            Deal Size : $250.0 million

                            Deal Type : Public Offering

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            03

                            MapLight Therapeutics

                            U.S.A arrow
                            AIChE Annual Meeting
                            Not Confirmed

                            MapLight Therapeutics

                            U.S.A arrow
                            AIChE Annual Meeting
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : ML-007C-MA

                            Therapeutic Area : Psychiatry/Psychology

                            Study Phase : Phase II

                            Sponsor : Jefferies

                            Deal Size : $262.3 million

                            Deal Type : Public Offering

                            DEALS_DEV arrow-down

                            MapLight illuminates $262M IPO plans to fund Cobenfy competitor

                            Details : In the public offering, ML-007C-MA, a miscellaneous product targeting the M1/M4 receptor, aims to advance treatment for schizophrenia.

                            Product Name : ML-007C-MA

                            Product Type : Miscellaneous

                            Upfront Cash : Undisclosed

                            October 07, 2025

                            Lead Product(s) : ML-007C-MA

                            Therapeutic Area : Psychiatry/Psychology

                            Highest Development Status : Phase II

                            Sponsor : Jefferies

                            Deal Size : $262.3 million

                            Deal Type : Public Offering

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            04

                            MapLight Therapeutics

                            U.S.A arrow
                            AIChE Annual Meeting
                            Not Confirmed

                            MapLight Therapeutics

                            U.S.A arrow
                            AIChE Annual Meeting
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : ML-007C-MA

                            Therapeutic Area : Psychiatry/Psychology

                            Study Phase : Phase II

                            Sponsor : Morgan Stanley

                            Deal Size : Undisclosed

                            Deal Type : Public Offering

                            DEALS_DEV arrow-down

                            MapLight Keeps Biopharma’s IPO Flame Alight To Advance Alzheimer’s, Schizophrenia Drugs

                            Details : The proceeds will help MapLight advance the clinical development of its current programs, including ML-007C-MA, an investigational agonist of the M1/M4 muscarinic receptors.

                            Product Name : ML-007C-MA

                            Product Type : Miscellaneous

                            Upfront Cash : Undisclosed

                            September 22, 2025

                            Lead Product(s) : ML-007C-MA

                            Therapeutic Area : Psychiatry/Psychology

                            Highest Development Status : Phase II

                            Sponsor : Morgan Stanley

                            Deal Size : Undisclosed

                            Deal Type : Public Offering

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            05

                            MapLight Therapeutics

                            U.S.A arrow
                            AIChE Annual Meeting
                            Not Confirmed

                            MapLight Therapeutics

                            U.S.A arrow
                            AIChE Annual Meeting
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : ML-007C-MA

                            Therapeutic Area : Psychiatry/Psychology

                            Study Phase : Phase II

                            Sponsor : Undisclosed

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            Study of ML-007C-MA Efficacy & Safety in Inpatient Adults with Schizophrenia

                            Details : ML-007C-MA is a Other Small Molecule drug candidate, which is currently being evaluated in Phase II clinical studies for the treatment of Schizophrenia.

                            Product Name : Undisclosed

                            Product Type : Miscellaneous

                            Upfront Cash : Inapplicable

                            June 26, 2025

                            Lead Product(s) : ML-007C-MA

                            Therapeutic Area : Psychiatry/Psychology

                            Highest Development Status : Phase II

                            Sponsor : Undisclosed

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            06

                            MapLight Therapeutics

                            U.S.A arrow
                            AIChE Annual Meeting
                            Not Confirmed

                            MapLight Therapeutics

                            U.S.A arrow
                            AIChE Annual Meeting
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : ML-007C-MA

                            Therapeutic Area : Neurology

                            Study Phase : Phase II

                            Sponsor : Undisclosed

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            A Study to Assess the Efficacy and Safety of ML-007C-MA for the Treatment of Alzheimer's Disease Psychosis

                            Details : ML-007C-MA is a Other Small Molecule drug candidate, which is currently being evaluated in phase II clinical studies for the treatment of Alzheimer Disease.

                            Product Name : Undisclosed

                            Product Type : Miscellaneous

                            Upfront Cash : Inapplicable

                            March 20, 2025

                            Lead Product(s) : ML-007C-MA

                            Therapeutic Area : Neurology

                            Highest Development Status : Phase II

                            Sponsor : Undisclosed

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            07

                            MapLight Therapeutics

                            U.S.A arrow
                            AIChE Annual Meeting
                            Not Confirmed

                            MapLight Therapeutics

                            U.S.A arrow
                            AIChE Annual Meeting
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : ML-007,Undisclosed

                            Therapeutic Area : Psychiatry/Psychology

                            Study Phase : Phase I

                            Sponsor : Undisclosed

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            MapLight Announces Phase 1 Results for M1/M4 Agonist in Schizophrenia and Alzheimer’s

                            Details : ML-007/PAC is an extended-release, fixed-dose combination of M1/M4 agonist, co-formulated with PAC. It is being investigated for schizophrenia and Alzheimer's disease psychosis.

                            Product Name : Undisclosed

                            Product Type : Miscellaneous

                            Upfront Cash : Inapplicable

                            December 02, 2024

                            Lead Product(s) : ML-007,Undisclosed

                            Therapeutic Area : Psychiatry/Psychology

                            Highest Development Status : Phase I

                            Sponsor : Undisclosed

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            08

                            MapLight Therapeutics

                            U.S.A arrow
                            AIChE Annual Meeting
                            Not Confirmed

                            MapLight Therapeutics

                            U.S.A arrow
                            AIChE Annual Meeting
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : ML-007

                            Therapeutic Area : Psychiatry/Psychology

                            Study Phase : Phase I

                            Sponsor : Undisclosed

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            Maplight Completes Phase 1 Trial for M1/m4 Agonist in Schizophrenia and Alzheimer's

                            Details : ML-007C-MA is a combination M1/M4 muscarinic agent. It is under phase 1 clinical development for the treatment of Schizophrenia & Alzheimer's disease psychosis.

                            Product Name : Undisclosed

                            Product Type : Miscellaneous

                            Upfront Cash : Inapplicable

                            January 03, 2024

                            Lead Product(s) : ML-007

                            Therapeutic Area : Psychiatry/Psychology

                            Highest Development Status : Phase I

                            Sponsor : Undisclosed

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            09

                            MapLight Therapeutics

                            U.S.A arrow
                            AIChE Annual Meeting
                            Not Confirmed

                            MapLight Therapeutics

                            U.S.A arrow
                            AIChE Annual Meeting
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : ML-007C-MA

                            Therapeutic Area : Psychiatry/Psychology

                            Study Phase : Phase I

                            Sponsor : Organovo Holdings

                            Deal Size : $225.0 million

                            Deal Type : Series C Financing

                            DEALS_DEV arrow-down

                            MapLight Therapeutics Closes $225 Million Series C Funding Round to Advance Pipeline of Central Nervous System...

                            Details : The net funding will advance ML-007C-MA, a novel M1/M4 muscarinic agonist agent combined with a precision matched peripheral muscarinic antagonist, into Phase 2 trials for schizophrenia and Alzheimer's disease psychosis in 2024.

                            Product Name : Undisclosed

                            Product Type : Miscellaneous

                            Upfront Cash : Undisclosed

                            October 31, 2023

                            Lead Product(s) : ML-007C-MA

                            Therapeutic Area : Psychiatry/Psychology

                            Highest Development Status : Phase I

                            Sponsor : Organovo Holdings

                            Deal Size : $225.0 million

                            Deal Type : Series C Financing

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            10

                            MapLight Therapeutics

                            U.S.A arrow
                            AIChE Annual Meeting
                            Not Confirmed

                            MapLight Therapeutics

                            U.S.A arrow
                            AIChE Annual Meeting
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : ML-007

                            Therapeutic Area : Psychiatry/Psychology

                            Study Phase : Phase I

                            Sponsor : Undisclosed

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            Maplight Therapeutics Announces Successful Completion of Second Phase 1 Clinical Trial of The Novel Muscarinic...

                            Details : ML-007, a novel M1/M4 muscarinic receptor agonist targeting brain circuits shown to be dysfunctional in neurodegenerative and neurocognitive disorders such as schizophrenia, Alzheimer's disease psychosis, and dyskinesias.

                            Product Name : Undisclosed

                            Product Type : Miscellaneous

                            Upfront Cash : Inapplicable

                            August 24, 2023

                            Lead Product(s) : ML-007

                            Therapeutic Area : Psychiatry/Psychology

                            Highest Development Status : Phase I

                            Sponsor : Undisclosed

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth